{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Oxytocin",
    "short_name": "Oxytocin",
    "aliases": [
      "pitocin",
      "oxytocin injection"
    ],
    "classification": {
      "category": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "needs_prescription": false,
      "notes": "Classification describes what Oxytocin is and the general domain where it appears."
    },
    "status": {
      "category": "approved_human",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-19",
      "human_use_note": "Status reflects how Oxytocin appears in clinical literature and/or real-world contexts. This is descriptive only."
    },
    "structure": {
      "sequence_oneletter": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "amino_acid_seq": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_formula": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_weight": null,
      "structure_image_url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "risk": {
      "current_score": 5,
      "severity": "moderate",
      "likelihood": "possible",
      "evidence_grade": "unknown",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "Risk scoring reflects evidence quality, adverse-signal plausibility, and uncertainty. Limited data increases uncertainty.",
      "risk_score": 5
    },
    "sections": {
      "overview": [
        {
          "claim_type": "overview",
          "title": "What it is",
          "population_group": "general",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Oxytocin is a bioactive compound discussed in research and/or clinical contexts. This entry summarizes what it is, what it is studied for, and key evidence limitations without providing protocols.",
          "evidence_refs": [
            "E1"
          ]
        }
      ],
      "use_cases": [],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "unit": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "min": null,
          "max": null,
          "frequency": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "duration": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "population_group": "general",
          "notes": "Descriptive only. Observed in studies; not instructions.",
          "evidence_refs": []
        }
      ],
      "developmental_risk_block": [
        {
          "claim_type": "risk",
          "population_group": "adolescent",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Developmental risk is flagged due to limited adolescent data and uncertain long-term effects. Endocrine, growth, neurodevelopmental, and metabolic setpoints may be sensitive to perturbation. This section is descriptive only; uncertainty is explicitly acknowledged.",
          "evidence_refs": []
        }
      ],
      "interaction_summary": [],
      "current_outlook_bullets": [
        "a bioactive compound discussed in research and/or clinical contexts",
        "this entry summarizes what it is, what it is studied for, and key evidence limitations without providing protocols",
        "general recovery and resilience interest (anecdotal)",
        "common biohacker curiosity due to community reports",
        "interest in mechanisms suggested by early evidence",
        "used in goal-based stacking discussions (anecdotal)",
        "exploration in wellness communities despite evidence limits"
      ]
    },
    "evidence": [
      {
        "id": "E1",
        "title": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "source_type": "pubmed",
        "source_id": "E1",
        "url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "published_date": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "evidence_grade": "unknown",
        "notes": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
      }
    ],
    "changelog": [
      {
        "date": "2026-01-19",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for Oxytocin",
        "detail": "Generated from queue ingestion (Phase 6). Requires human-authored, evidence-bounded content.",
        "evidence_refs": []
      }
    ],
    "needs_prescription": true,
    "meta": {
      "priority": "normal",
      "notes_seed": "FDA-approved oxytocin (Rx) uterotonic; include only label-level indications; no protocols."
    },
    "topics": {
      "primary": [
        "topic_hormonal_endocrine"
      ]
    },
    "slug": "oxytocin"
  },
  "canonical_name": "Oxytocin",
  "interactions": {
    "drug_classes": [],
    "supplement_classes": [],
    "peptides": []
  },
  "practical": {
    "schema_version": "practical_block_v1",
    "bottom_line": "Oxytocin is a human hormone used medically in obstetrics; off-label wellness use focuses on mood and social effects. Evidence for these effects is mixed, and side effects depend on route and context.",
    "benefits": [
      "Clinical use in labor and postpartum bleeding control (medical setting)",
      "Interest in social bonding / affiliative behavior effects (research and user interest)",
      "Interest in anxiety modulation in select contexts (mixed evidence)"
    ],
    "side_effects_common": [
      "Headache",
      "Nausea",
      "Dizziness",
      "Nasal irritation (intranasal use)",
      "Fatigue"
    ],
    "side_effects_serious": [
      "Significant blood pressure changes, fainting, or chest pain",
      "Severe allergic reaction (hives, facial swelling, trouble breathing)",
      "Confusion, severe headache, or seizures (electrolyte disturbance risk)",
      "Uterine cramping/bleeding outside appropriate medical supervision"
    ],
    "who_should_be_cautious": [
      "Pregnant individuals (obstetric effects are primary and clinically significant)",
      "People with significant cardiovascular disease or arrhythmia history",
      "People with seizure disorders or history of severe hyponatremia",
      "Anyone under 18"
    ]
  }
}
